Advertisement

Organisation › Details
Mount Sinai Health System (New York)
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care. The System includes approximately 6,600 primary and specialty care physicians, 12-minority-owned free-standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report. *
![]() |
Industry | medicine |
Industry 2 | hospitals | |
![]() |
Region | New York, NY |
Country | United States (USA) | |
Street | One Gustave L. Levy Place | |
City | 10029 New York, NY | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2023-06-24 |
Advertisement

More documents for Mount Sinai Health System (New York)
- [1] Landos Biopharma, Inc.. (1/4/21). "Press Release: Landos Biopharma Announces Positive Results from a Phase 2 Trial of Oral BT-11 for Patients with Ulcerative Colitis". Blacksburg, VA....
- [2] Landos Biopharma, Inc.. (7/14/20). "Press Release: Landos Biopharma Announces First Human Dosing in a Phase 1 Study of NX-13, Its Novel Candidate for Inflammatory Bowel Disease". Blacksburg, VA....
- [3] Fluidigm Corporation. (3/16/20). "Press Release: Consortium of Medical Schools Led by Mount Sinai Fast-Tracking COVID-19 Detection Test Utilizing Fluidigm Microfluidics Technology". South San Francisco, CA....
- [4] Landos Biopharma, Inc.. (8/20/19). "Press Release: Landos Biopharma Announces First Patient Dosed in Global Phase 2 Trials of BT-11 in Ulcerative Colitis". Blacksburg, VA....
- [5] Fluidigm Corporation. (3/28/19). "Press Release: Fluidigm Introduces the First Complete Sample-to-Answer Solution for Deep Immune Profiling by Mass Cytometry". South San Francisco, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top